Back to News
Market Impact: 0.2
Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Tiziana Life Sciences signed a memorandum of understanding with King Abdullah International Medical Research Center (KAIMRC) related to its immunomodulation-therapy development efforts. The announcement supports external clinical and research collaboration around Tiziana's lead intranasal foralumab candidate, though no financial terms, trial details, or commercialization commitments were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
TLSA0.45
More News
- Tiziana Life Sciences stock jumps on MS trial partnership
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for CFA Charterholders: An Evidence Standard
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data